The objective is to better identify suspicious breast lesions that need to be biopsied for malignancy in women currently recommended for biopsy. The long-term goal is to reduce unnecessary biopsies and increase biopsy yield. To do this, the investigators have developed an innovative way to use FDA-approved breast imaging protocols to acquire multispectral images to measure the composition of suspicious breast lesions. The central hypothesis is that breast tissue composition in combination with analysis of morphological and textural tissue characteristics on digital breast tomosynthesis (DBT) imaging will yield significantly higher breast cancer specificity than conventional interpretation of DBT alone.
Breast Cancer
The objective is to better identify suspicious breast lesions that need to be biopsied for malignancy in women currently recommended for biopsy. The long-term goal is to reduce unnecessary biopsies and increase biopsy yield. To do this, the investigators have developed an innovative way to use FDA-approved breast imaging protocols to acquire multispectral images to measure the composition of suspicious breast lesions. The central hypothesis is that breast tissue composition in combination with analysis of morphological and textural tissue characteristics on digital breast tomosynthesis (DBT) imaging will yield significantly higher breast cancer specificity than conventional interpretation of DBT alone.
Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis
-
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States, 33612
Hawaii Radiology Associates, LTD (East Hawaii Women's Imaging Center), Hilo, Hawaii, United States, 96720
The Queen's Medical Center, Honolulu, Hawaii, United States, 96822
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
20 Years to 85 Years
FEMALE
No
University of Hawaii,
John A Shepherd, PhD, PRINCIPAL_INVESTIGATOR, University of Hawaii Cancer Research Center
2026-07